Amendment No. 12 to Schedule 13D Filing for REVIVA PHARMACEUTICALS HOLDINGS, INC.

This filing, Amendment No. 12 to Schedule 13D, concerns REVIVA PHARMACEUTICALS HOLDINGS, INC. and details changes in beneficial ownership reported by Parag Saxena and Vedanta Partners, LLC. As of December 18, 2025, Vedanta Partners, LLC beneficially owns 5.2% of the outstanding Common Stock, holding 6,268,006 shares. Parag Saxena directly holds 900,937 shares and is deemed to beneficially own 5.2% of the outstanding Common Stock, with an aggregate of 6,268,006 shares. The filing indicates that Vedanta Partners, LLC ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock on December 18, 2025. The Reporting Persons have not effected any transactions in the past sixty days, except for options granted to Mr. Saxena on December 18, 2025, in connection with his director service. The ownership percentages are based on 116,849,932 outstanding shares as of December 18, 2025.